Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis.
Savage TM, Fortson KT, de Los Santos-Alexis K, Oliveras-Alsina A, Rouanne M, Rae SS, Gamarra JR, Shayya H, Kornberg A, Cavero R, Li F, Han A, Haeusler RA, Adam J, Schwabe RF, Arpaia N. Savage TM, et al. Among authors: adam j. Immunity. 2024 Feb 13;57(2):303-318.e6. doi: 10.1016/j.immuni.2024.01.009. Epub 2024 Feb 2. Immunity. 2024. PMID: 38309273
Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications: S. A. M. Wankowicz, L. Werner, A. Orsola, J. Novak, M. Bowden, T. K. Choueiri, I. de Torres, J. Morote, G. J. Freeman, S. Signoretti and J. Bellmunt J Urol 2017;198:817-823.
Rouanne M, Lebret T, Radulescu C, Adam J. Rouanne M, et al. Among authors: adam j. J Urol. 2018 Mar;199(3):854-856. doi: 10.1016/j.juro.2017.09.145. Epub 2017 Nov 24. J Urol. 2018. PMID: 29179001 No abstract available.
BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer.
Rouanne M, Adam J, Radulescu C, Letourneur D, Bredel D, Mouraud S, Goubet AG, Leduc M, Chen N, Tan TZ, Signolle N, Bigorgne A, Dussiot M, Tselikas L, Susini S, Danlos FX, Schneider AK, Chabanon R, Vacher S, Bièche I, Lebret T, Allory Y, Soria JC, Arpaia N, Kroemer G, Kepp O, Thiery JP, Zitvogel L, Marabelle A. Rouanne M, et al. Among authors: adam j. J Clin Invest. 2022 Jun 15;132(12):e145666. doi: 10.1172/JCI145666. J Clin Invest. 2022. PMID: 35503263 Free PMC article.
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S. Chabanon RM, et al. Among authors: adam j. J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11. J Clin Invest. 2019. PMID: 30589644 Free PMC article.
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancer.
Rouanne M, Adam J, Goubar A, Robin A, Ohana C, Louvet E, Cormier J, Mercier O, Dorfmüller P, Fattal S, de Montpreville VT, Lebret T, Dartevelle P, Fadel E, Besse B, Olaussen KA, Auclair C, Soria JC. Rouanne M, et al. Among authors: adam j. BMC Cancer. 2016 Jul 15;16:483. doi: 10.1186/s12885-016-2541-5. BMC Cancer. 2016. PMID: 27422280 Free PMC article.
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy.
Gataa I, Mezquita L, Rossoni C, Auclin E, Kossai M, Aboubakar F, Le Moulec S, Massé J, Masson M, Radosevic-Robin N, Alemany P, Rouanne M, Bluthgen V, Hendriks L, Caramella C, Gazzah A, Planchard D, Pignon JP, Besse B, Adam J. Gataa I, et al. Among authors: adam j. Eur J Cancer. 2021 Mar;145:221-229. doi: 10.1016/j.ejca.2020.10.017. Epub 2021 Jan 27. Eur J Cancer. 2021. PMID: 33516050
1,182 results